RESUMEN
Radical prostatectomy is a primary treatment option for localized prostate cancer (PCa), although high rates of recurrence are commonly observed postsurgery. Photodynamic therapy (PDT) has demonstrated efficacy in treating nonmetastatic localized PCa with a low incidence of adverse events. However, its limited efficacy remains a concern. To address these issues, various organic polymeric nanoparticles (OPNPs) loaded with photosensitizers (PSs) that target prostate cancer have been developed. However, further optimization of the OPNP design is necessary to maximize the effectiveness of PDT and improve its clinical applicability. This Review provides an overview of the design, preparation, methodology, and oncological aspects of OPNP-based PDT for the treatment of PCa.
RESUMEN
In order to synchronously improve mechanical and flame retardant properties of polylactide/poly(butylene adipate-co-terephthalate) (PLA/PBAT) composites, a series of multifunctional composites containing multi-walled carbon nanotubes (CNTs), ammonium polyphosphate (APP) and a commercial multifunctional epoxy oligomer (MEO) as chain extender were prepared via melt blending. The results show that the optimal flame retardant properties of PLA5-PBAT5/10A/6C composite containing 6 % CNTs and 10 wt% APP, presented the limited oxygen index reached 28.3 % and exhibited a decrease in peak heat release rate (pHRR) and total heat release (THR) to 368 kJ/m2 and 72 MJ/m2, respectively because of the co-continuous phase, CNTs network and condensed effect of APP. Meanwhile, the construction of co-continuous phases endows PLA5-PBAT5 with better mechanical compared to PLA8-PBAT2 composites. The elongation at break reaches (245.9 %) and notched impact strength (16.5 kJ/m2) of PLA5-PBAT5/10A/6C were higher than the PLA8-PBAT2/10A/6C by 16.0 and 283.7 %.
Asunto(s)
Compuestos de Amonio , Retardadores de Llama , Nanotubos de Carbono , Polifosfatos , Poliésteres , AdipatosRESUMEN
OBJECTIVE: To investigate the effect of inflammation-related genes on the prognosis of prostate cancer (PCa). METHODS: We downloaded PCa-related clinical data and mRNA sequencing data from the database Cancer Genome Atlas (TCGA) and inflammation-related pathway gene sets from MsigDB. Using univariate regression and LASSO regression analyses, we screened inflammation-related genes for the construction of a prognostic risk model and evaluated the performance of the model in predicting the prognosis of PCa by Kaplan-Meier and ROC analyses. Based on the nomogram, we calculated the risk scores of the patients, divided them into a high-risk and a low-risk group based on the median values of their risk scores, identified differentially expressed genes for enrichment analysis and verified the expression level of SPHK1 in the PCa tissue microarrays by immunohistochemical staining. RESULTS: Totally 19 inflammation-related genes were identified from 172 candidate genes for the construction of the prognostic risk model, including the risk genes CD14, PIK3R5, GABBR1, RELA, IRF7, SCARF1, MSR1, SPHK1, OSM and STAB1, and the protective genes AQP9, LPAR1, ATP2C1, NDP, CXCL6, P2RY2, DCBLD2, PCDH7, and IFNAR1. Kaplan-Meier analysis showed that the patients with high risk scores had a significantly lower recurrence-free survival and a worse prognosis than those with low risk scores. Differentially expressed genes were involved mainly in the activation of inflammatory response pathways. Immunohistochemical results indicated that the expression of SPHK1 was significantly higher in the tumorous than in the normal tissue and increased with the Gleason score. There was a correlation between the SPHK1 expression and envelope invasion. CONCLUSION: The prognostic risk model of inflammation-related genes constructed based on the TCGA database can effectively predict the prognosis of PCa.